This is a listing of clinical trials recently activated by the University of Illinois Cancer Center Clinical Trials Office for patient enrollment. Click the study links below to learn details regarding the studies on clinicaltrials.gov. You can also search for other clinical trials on our website. For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.
Protocol Title: DESTINY-Biliary Tract Cancer-01: Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-Expressing Biliary Tract Cancer
Sponsor: AstraZeneca Pharmaceuticals LP
Investigator: Shikha Jain, MD
Protocol Title: DeLLphi-312: A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination with Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (AMG2024-0178)
Sponsor: Amgen
Investigator: Frank Weinberg, MD, PhD
Protocol Title: MK-2870-011: A Phase 3, Randomized, Open-Label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse 11)
Sponsor: Merck, Sharpe & Dohme Corp.
Investigator: Abiola Ibraheem, MD
